Neuberger Berman Group
VTYX

Neuberger Berman Group’s Ventyx Biosciences VTYX Stock Holding History

Neuberger Berman Group’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,261
Closed -$24.1K – 2150
2025
Q2 		$24.1K Buy
+11,261
New +$18.2K ﹤0.01% 2016

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group's VTYX Position: Q3 2025 in Review

Neuberger Berman Group sold out of Ventyx Biosciences (VTYX) in Q3 2025, closing a stake of 11,261 shares — an estimated $24.1K sold.

Neuberger Berman Group first reported a position in VTYX in Q2 2025 and held it in 1 quarter. The position peaked at $24.1K in Q2 2025. 110 funds tracked by Wall St. Rank hold VTYX as of Q3 2025.

  • Neuberger Berman Group reported no remaining Ventyx Biosciences position as of Q3 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 11,261 Ventyx Biosciences shares in Q3 2025, an estimated $24.1K.
  • Neuberger Berman Group first reported a position in Ventyx Biosciences in Q2 2025 and held it in 1 quarter.
  • Neuberger Berman Group's Ventyx Biosciences position peaked at $24.1K in Q2 2025.
  • 110 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2025.

Based on Neuberger Berman Group's 13F filing for Q3 2025, filed 12 Nov 2025.